Sign In
Buy ETON
$27.61
+0.210 (+0.766%)
At Close: Jun 03, 2026
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
10:55am, Friday, 20'th Mar 2026
The mean of analysts' price targets for Eton Pharmaceuticals (ETON) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
06:42pm, Thursday, 19'th Mar 2026
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
06:30pm, Thursday, 19'th Mar 2026
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Thursday, 19'th Mar 2026
DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercia
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
04:30pm, Tuesday, 03'rd Mar 2026
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercia
DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercia
US FDA approves Eton Pharma's hormonal disorder drug
01:51pm, Wednesday, 25'th Feb 2026
The U.S. Food and Drug Administration approved on Wednesday Eton Pharmaceuticals' oral liquid therapy for a rare childhood hormonal disorder, giving families an easier way to manage the condition and
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
01:47pm, Wednesday, 25'th Feb 2026
DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
06:50am, Friday, 20'th Feb 2026
DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
06:50am, Monday, 02'nd Feb 2026
DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
10:20am, Friday, 23'rd Jan 2026
Eton offers a diversified, acquisition-driven portfolio in ultra-rare pediatric endocrinology and metabolic diseases, targeting significant peak sales potential. My DCF-based Fair Value is $28.1, repr
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
04:30pm, Monday, 24'th Nov 2025
DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Acadian Asset Management LLC Sells 9,713 Shares of Eton Pharmaceuticals, Inc. $ETON
03:14am, Friday, 14'th Nov 2025
Acadian Asset Management LLC decreased its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 2.4% during the second quarter, according to its most recent filing with the Securities an
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
04:30pm, Wednesday, 12'th Nov 2025
DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript
11:16pm, Thursday, 06'th Nov 2025
Eton Pharmaceuticals, Inc. ( ETON ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - President, CEO & Director James Grub
